Skip to main content
OpenTrials

Clinical trial condition

Lymphatic Diseases

Explore clinical trials studying Lymphatic Diseases. Study availability and eligibility vary by location and protocol.

8,991 public trials 1,838 recruiting studies
Refine in advanced search Browse all conditions

Lymphatic Diseases trial results

Completed

Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

NCT04833114

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • UK Graz Universitätsklinik für Innere Medizin Klinische Abteilung für Hämatologie Graz, Austria
  • LKH Hochsteiermark Standort Leoben Abteilung für Innere Medizin Department für Hämato-Onkologie Leoben, Austria
  • Ordensklinikum Linz GmbH- Elisabethinen: I. Interne Abteilung Hämato-Onkologie Linz, Austria
  • Kepler Universitätsklinikum Med Campus III, Univ.-Klinik für Hämatologie und Internistische Onkologie Linz, Austria
View all 64 locations
View Trial Details
Completed

Health-Related Quality of Life Outcomes in Patients With Aggressive B-Cell Lymphomas Treated With CAR-T Cell Therapy in Real Life

NCT06026644

Conditions
DLBCL - Diffuse Large B Cell Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Hemic and Lymphatic Diseases, +5 more
Locations
  • Aou Di Bologna - Policlinico S. Orsola-malpighi - Uoc Ematologia Bologna, Italy
  • Asst Degli Spedali Civili Di Brescia - Ssvd Centro Trapianti Midollo Per Adulti - Cattedra Di Ematologia Brescia, Italy
  • AOU Careggi - SOD terapie cellulari e Medicina Trasfusionale Florence, Italy
  • Irccs Aou San Martino - Genova - Uo Ematologia E Trapianti Genova, Italy
View all 13 locations
View Trial Details
Completed

Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma

NCT02242097

Conditions
Contiguous Stage II Mantle Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations
  • Northwestern University Chicago, Illinois, United States
  • Northwestern University- Lake Forest Hospital Lake Forest, Illinois, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Cleveland Clinic Cleveland, Ohio, United States
View Trial Details
Completed

A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)

NCT03494179

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Anhui Province Cancer Hospital Hefei, Anhui, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Peking Union Medical College Hospital Beijing, Beijing Municipality, China
  • Beijing Cancer Hospital Beijing, Beijing Municipality, China
View all 31 locations
View Trial Details
Completed

Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis

NCT05415137

Conditions
Fibrosis, Granuloma, Hemic and Lymphatic Diseases, +15 more
Locations
  • aTyr Investigative Site Birmingham, Alabama, United States
  • aTyr Investigative Site Phoenix, Arizona, United States
  • aTyr Investigative Site Los Angeles, California, United States
  • aTyr Investigative Site Sacramento, California, United States
View all 91 locations
View Trial Details
Completed

Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

NCT01868451

Conditions
Hemic and Lymphatic Diseases, Hodgkin Disease, Hodgkin Lymphoma, +7 more
Locations
  • City of Hope Duarte, California, United States
  • Stanford University Medical Center Stanford, California, United States
  • Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
View Trial Details
Completed

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

NCT04502030

Conditions
Agammaglobulinemia, Blood Protein Disorders, Chronic Disease, +18 more
Locations
  • Octapharma Research Site St. Petersburg, Florida, United States
  • Octapharma Research Site Columbus, Georgia, United States
  • Octapharma Research Site Macon, Georgia, United States
  • Octapharma Research Site New Orleans, Louisiana, United States
View all 84 locations
View Trial Details

Related conditions